LAKEWOOD, Colo.--(BUSINESS WIRE)--CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, announced that the Belgian Red Cross-Flanders (BCR-F) has chosen CaridianBCT’s Mirasol® Pathogen Reduction Technology System as their technology of choice for improving the safety of platelet products.
“As the largest blood provider in Belgium, the BRC-F is known in the industry to be at the forefront of implementing new and advanced safety measures, maintaining high standards of quality and safety,” said Teresa Ayers, senior vice president of Pathogen Reduction Technologies at CaridianBCT. “To be selected as their preferred solution for pathogen reduction of platelets is an exciting milestone for our technology and establishes the Mirasol system as a leader in blood safety.”
The BRC-F selected CaridianBCT’s Mirasol system after thorough in-vitro evaluations of platelet quality and operational efficiency and a successful in-vivo patient study. The introduction of the Mirasol system will allow the BRC-F to be in compliance with the Belgian mandate to pathogen reduce all platelet products by July 2011.
The Mirasol system uses the unique properties of riboflavin (vitamin B2), a naturally occurring compound, and ultraviolet light to inactivate disease-causing agents including viruses, bacteria, parasites and white blood cells that may be present in blood components for transfusion. Providing the BRC-F with a full service solution, the Mirasol system will be able to accommodate all platelet products—including whole-blood derived and apheresis platelets—on a single platform. In addition, the Mirasol system’s operational and logistical benefits will allow BRC-F to implement this innovative technology in a cost effective manner.
CaridianBCT has enjoyed a long-standing relationship with the BRC-F as they have relied on the Trima Accel® Blood Collection System and COBE® Spectra Apheresis System for automated component collections and therapeutic apheresis needs. This relationship is further strengthened by the BCR-F’s decision to implement the Mirasol system as the pathogen reduction technology solution of choice.
About the Mirasol System:
The only device on the market to use a combination of riboflavin (vitamin B2), a non-toxic naturally occurring compound, and ultraviolet light, the Mirasol system delivers immediately transfusable blood products, enabling blood centers to release pathogen reduced blood products for timely patient care. CaridianBCT received a CE Mark in 2007 for the Mirasol system for treating platelets suspended in plasma. A second CE Mark was received in 2008 for treating fresh frozen plasma (FFP) in addition to treating plasma-reduced platelet concentrates that are subsequently stored in Platelet Additive Solution. The Mirasol system is available for sale in countries where the CE mark is accepted and is not currently available for sale in the United States.
CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies. The company serves patients through its commitment “For Better Blood and Better Lives” by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit www.caridianbct.com.